Relmada Therapeutics is betting on a new bladder cancer treatment designed to be easier for everyday clinics to use, at a time when current options face supply and safety headaches. It also has a second drug aimed at hard-to-treat compulsive behavior disorders, but the whole story depends on upcoming trial results and the company’s ability to fund development without setbacks.Read more
Relmada Therapeutics is betting on a new bladder cancer treatment designed for outpatient clinics, aiming to help patients who currently face major surgery, but it still has to clear late-stage trials. A fresh patent filing and a second early program add upside, yet clinical results, competition, and drug-protection setbacks could derail the story.Read more
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?Read more
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
